Extracts standardized to beta-glucans; varies by mushroom.
Review: medicinal mushrooms have a wide range of activities (anti-inflammatory, antioxidant, immunomodulatory, neuroprotective, lipid-lowering, etc.). Interest is growing, but more clinical trials are needed, along with safe and pure supplements. Much of the evidence is still laboratory-based.
View the study (study) →⏱ 3 min read
Medicinal mushrooms are a group of fungal species with documented traditional use in Asian pharmacopoeias (especially Chinese, Japanese, Korean, and Tibetan) for more than 2,000 years for immune strengthening, stress adaptation, longevity, and oncology adjunct therapy; the main members of this family with significant clinical and commercial backing are reishi (Ganoderma lucidum), shiitake (Lentinula edodes), maitake (Grifola frondosa), lion's mane (Hericium erinaceus), cordyceps (Ophiocordyceps sinensis), turkey tail (Trametes versicolor), and, to a lesser extent, chaga (Inonotus obliquus); each species has its own specific profile in this database with details on particular indications.
Modern scientific interest in medicinal mushrooms centers on two main families of active components: beta-glucans (especially beta-1,3/1,6-glucans from the fruiting body or the mycelium), complex polysaccharides with well-documented immunomodulatory activity that act as agonists of specific receptors of the innate immune system (Dectin-1, complement receptors), and the minor secondary compounds (triterpenoids, sterols, alkaloids, peptides) that vary enormously between species and are responsible for each mushroom's particular specific indications (the neuroprotective effect of lion's mane through hericenones, the adaptogenic-athletic effect of cordyceps through cordycepin, the oncology-adjunct effect of turkey tail through PSK and PSP).
The biological effect shared by practically all relevant medicinal mushrooms is modulation of the immune system through beta-glucans: these polysaccharides activate macrophages, dendritic cells, NK cells, and T lymphocytes in in vitro and in vivo studies, a mechanistic basis that has been used to postulate their use in recurrent infections, immune deficiencies, as an adjunct during chemotherapy and radiotherapy for cancer, and as a general immune tonic.
The clinical data vary by indication: as an oncology adjunct in some specific cancers (especially gastrointestinal), the PSK and PSP preparations derived from Trametes versicolor are marketed as medicines in Japan and China, with good-quality clinical trial data showing improvements in survival and quality of life when added to standard chemotherapy; in recurrent respiratory infections in children and athletes, several small trials have shown reductions in frequency with supplementation over months; in the immunity of healthy adults, the effects are more modest.
In integrative oncology, medicinal mushrooms (especially reishi, turkey tail, and maitake) are used with some frequency as adjuncts during treatment; several meta-analyses (some from the Cochrane registry) confirm benefits in immune parameters and quality of life, without demonstrating significant direct antitumor effects as a stand-alone treatment; integrative use benefits from coordination with the oncology team to avoid interactions with specific chemotherapy.
Cordyceps specifically has an adaptogenic profile with data on improving endurance athletic performance and tolerance to chronic stress; reishi has a more sedative profile and is a "longevity tonic"; lion's mane has a unique neuroprotective profile with effects on cognitive function.
A fundamental issue with medicinal mushrooms is the quality and composition of commercial products: there are important differences between fruiting body extracts (the classically medicinal part, with a higher concentration of specific secondary compounds) and extracts of mycelium grown on grain substrates (cheaper but with a different biochemical profile and often with a lot of residual starch from the substrate); premium products declare their origin, the part used (fruiting body vs mycelium), the concentration of beta-glucans and polysaccharides, and often the content of specific compounds that serve as quality markers for each species.
Doses vary by species and indication: typically 500-3,000 mg/day of standardized dry fruiting body extract, divided into 1-2 doses with or without food; the effects on immunity and adaptation appear gradually and require at least 4-12 weeks for clinical evaluation; combinations of several mushrooms in commercial formulations are common and may offer a broader profile than a single mushroom on its own.
Generally well tolerated, with documented use over millennia; the adverse effects described are rare and mild (digestive discomfort, occasionally skin rash); people with mushroom allergy may have allergic reactions and should be cautious; those taking anticoagulants should be cautious because of the mild antiplatelet effect described in several mushrooms (especially reishi); those taking immunosuppressants should avoid them because of a pharmacodynamic interaction with the immunomodulatory activity; people with active autoimmune diseases should exercise theoretical caution; they are contraindicated in people with organ transplants; in pregnancy and breastfeeding, data are limited, although they have traditionally been used without significant problems at moderate doses; cheap products may be contaminated with heavy metals (mushrooms are notable bioaccumulators of metals from the substrate), and it is advisable to choose products with purity certification and heavy metal analysis.
Information, not medical advice. Scientific evidence reflects the quality of the studies.